Адрес и телефон

Categorization using new american college of cardiology/american heart association guidelines for cholesterol management and its relation to alirocumab treatment following acute coronary syndromes

01 июн июня 2019
2019

Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes 
Matthew T. Roe El, MD, MHS Qian H. Li, ScD Deepak L, Bhatt, MD, MPH Vera A. Bittner, MD, MSPH Rafael Diaz, MD Shaun G. Goodman, MD, MSc Robert A. Harrington, MD J. Wouter Jukema, MD, PhD Patricio Lopez-Jaramillo, MD Renato D. Lopes, MD, PhD Michael J. Louie, MD, MPH, MSc Patrick M. Moriarty, MD Michael Szarek, PhD Robert Vogel, MD Harvey D. White, DSc Andreas M. Zeiher, MD Marie T. Baccara-Dinet, MD Ph. Gabriel Steg, MD Gregory G. Schwartz, MD, PhD For the ODYSSEY OUTCOMES InvestigatorsDuke Clinical Research Institute, Durham, NC (M.T.R., R.D.L.).Regeneron Pharmaceuticals, Tarrytown, NY (Q.H.L., M.J.L.).Brigham and Women's Hospital, Boston, MA (D.L.B.).University of Alabama at Birmingham (V.A.B.).

Estudios Clinicos Latinoamerica, Institute Cardiovascular de Rosario, Argentina (R.D.).St Michael's Hospital, Toronto, Canada (S.G.G.).Stanford University Medical Center, CA (R.A.H.).Leiden University Medical Center, the Netherlands (J.W.J.).Fundacion Oftalmologica de Santander (FOSCAL), Medical School (UDES), Floridablanca, Colombia (P.L.-J.).University of Kansas Medical Center, Kansas City, MO (P.M.M.).State University of New York (SUNY) Downstate Medical Center, Downstate School of Public Health, Brooklyn (M.S.).University of Colorado, Aurora (R.V., G.G.S.).Green Lane Cardiovascular Services, Auckland City Hospital, New Zealand (H.D.W.).Department of Medicine III, Goethe University, Frankfurt am Main, Germany (A.M.Z.).

Sanofi, Montpellier, France (M.T.B.- D.).Assistance Publique-Hopitaux de Paris, HOpital Bichat, Universite de Paris, FACT (French Alliance for Cardiovascular Trials), Institut National de la Sante et de la Recherche Medicale (INSERM) U1148, France (P.G.S.).National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, London, UK (P.G.S.). Originally published 2 Sep 20191https://doi.org110.1161/CIRCULATIONAHA.119.042551 1Circulation. 2019;140:1578-1589 


23.07.2020

ЦЕЛИ: Предварительный анализ выявил степень, в которой алирокумаб уменьшал общие (первые и последующие) нефатальные сердечно-сосудистые события и смертность от всех причин в исходах ODYSSEY.

23 июля 2020
#Статьи
14.02.2020

BACKGROUND:After ACS, alirocumab added to intensive stain therapy favourably impacted on Type l and 2 MIs.

14 февраля 2020
#Статьи

powered by